share_log

Johnson & Johnson | 10-K: FY2023 Annual Report

SEC ·  Feb 17 05:19

Summary by Futu AI

Johnson & Johnson (J&J) has reported a 6.5% increase in worldwide sales to $85.2 billion for the year 2023, compared to the previous year. U.S. sales saw a 10.6% rise, while international sales grew by 1.9%. The company's Innovative Medicine segment contributed $54.8 billion, up 4.2% from 2022, with significant growth in products like STELARA and TREMFYA. The MedTech segment also saw a 10.8% increase in sales to $30.4 billion, bolstered by acquisitions and operational growth. Despite these gains, J&J faces cybersecurity threats that could impact its business and financial condition. The company has established privacy compliance programs but acknowledges the risk of information security incidents. J&J also anticipates challenges following the separation of Kenvue Inc., including potential tax liabilities and the inability to predict Kenvue...Show More
Johnson & Johnson (J&J) has reported a 6.5% increase in worldwide sales to $85.2 billion for the year 2023, compared to the previous year. U.S. sales saw a 10.6% rise, while international sales grew by 1.9%. The company's Innovative Medicine segment contributed $54.8 billion, up 4.2% from 2022, with significant growth in products like STELARA and TREMFYA. The MedTech segment also saw a 10.8% increase in sales to $30.4 billion, bolstered by acquisitions and operational growth. Despite these gains, J&J faces cybersecurity threats that could impact its business and financial condition. The company has established privacy compliance programs but acknowledges the risk of information security incidents. J&J also anticipates challenges following the separation of Kenvue Inc., including potential tax liabilities and the inability to predict Kenvue's stock performance. The company's future plans include divesting its ownership interest in Kenvue, although the timing remains uncertain. J&J's Board of Directors has approved a share repurchase program, with $5.0 billion of common stock repurchased in fiscal 2023. The company's subsidiaries operate 61 manufacturing facilities worldwide, with a focus on maintaining these properties in good condition. J&J's executive officers have been elected by the Board to hold office for one year, with no family relationships or arrangements influencing their selection.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.